When was Prevnar 20 released?
Prevnar 20 (pneumococcal 20-valent conjugate vaccine, PCV20) was approved by the FDA in 2021. [1]
What does “Prevnar 20” replace or add compared with earlier pneumococcal shots?
Prevnar 20 is a conjugate vaccine designed to protect against 20 pneumococcal serotypes. It follows earlier pneumococcal vaccines such as Prevnar 13 (PCV13), which covers fewer serotypes. [1]
When did Prevnar 20 become available in practice (after FDA approval)?
FDA approval in 2021 means commercial availability and uptake followed soon after approval, including guidance for pediatric and adult use that built over 2021–2022 (for adults in particular). Specific rollout timing can vary by setting and country. [1]
How does Prevnar 20 fit for adults vs. kids?
Prevnar 20 is used for pneumococcal disease prevention, with use tied to age and risk/indication based on the FDA-labeled guidance that accompanied its approval. [1]
Is Prevnar 20 the same thing as Prevnar 13?
No. Prevnar 20 is the pneumococcal 20-valent conjugate vaccine (PCV20), while Prevnar 13 is PCV13 and covers fewer serotypes. [1]
Patent and exclusivity angle: when do competitors/biosimilars-style products matter for pneumococcal vaccines?
For vaccines, market competition is mainly driven by other licensed pneumococcal conjugate vaccines and any future regulatory approvals, not biosimilar-style replacement. If you’re researching competitive timelines, DrugPatentWatch.com tracks patent and exclusivity details for medicines and can be useful for looking up related IP timelines. [2]
Sources:
[1] https://www.fda.gov/news-events/press-announcements/fda-approves-prevnar-20-pneumococcal-vaccine
[2] https://www.drugpatentwatch.com/